C1 Esterase Inhibitor
Average cost per year*
Average cost per beneficiary*
This medication is used to treat the swelling problems that occur with a certain immune disease passed down through families (hereditary angioedema-HAE). HAE is caused by low levels or improper function of a natural substance produced by the body (C1-inhibitor). Symptoms such as rapid swelling of the hands, feet, limbs, face, tongue, or throat can occur. Swelling of the intestinal tract may cause symptoms such as abdominal cramps, diarrhea, or vomiting. Attacks of swelling may occur without reason. However, anxiety, stress, sickness, and surgery may trigger attacks in some people. This medication increases the level of C1-inhibitor to help treat attacks of sudden swelling due to hereditary angioedema. NOTE: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
*Origin of the terms and chart data used within this page: https://data.cms.gov/
Yes, Berinert is covered by Medicare.
In 2021, the average cost per dose of Berinert was $2,588.33.
The average dose of Berinert received per year is 13,276 units
68 Medicare beneficiaries received Berinert in 2021, which was a 0.03% from 2020
There were 428 claims made by Medicare beneficiaries, which is a 0.02% from 2020
The average spending amount per claim in 2021 was $94,504.36
The average Medicare spending per beneficiary amount for Berinert was $594,821.53
CSL Behring LLC received $40,447,864.35
The total amount spent on Berinert by Medicare is $40,447,864.35
Short Term Medical Insurance
Limited Fixed Indemnity Plans